Morphine and Metabolites on Synergi Polar-RP (direct injection after PPT)
LC Conditions
Column
Synergi 4 µm Polar-RP 80 Å, LC Column 100 x 2 mm, Ea
Brand
Synergi
Part No
00D-4336-B0
Phase Name
Polar-RP
Elution Type
Gradient
Mobile Phase
A: 0.1% Formic Acid in Water
B: 0.1% Formic Acid in Acetonitrile
Gradient Profile
Step No.
Time(min)
%A
%B
1
0
97
3
2
2
97
3
3
4.8
50
50
Flow Rate
0.40 mL/min
Temperature
22°C
Detection
Mass Spectrometer (MS) @ (22°C)
Detection Info
Sample Notes
SecurityGuard™ Guard Cartridge System extends column lifetime. - SecurityGuard Cartridges, POLAR-RP 4 x 2.0mm, 10/Pk Part No.: AJ0-6075 - Holder Part No.: KJ0-4282
Order Items Used in This Application
- 1. Morphine
- 2. Normorphine
- 3. Morphine-3-beta-D-glucuronide
-OEChem-05081000442D<br><br> 40 44 0 1 0 0 0 0 0999 V2000<br> 2.2314 0.0528 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.0000 -2.4021 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.0000 2.4021 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0<br> 6.1607 -0.9511 0.0000 N 0 0 3 0 0 0 0 0 0 0 0 0<br> 3.6897 -0.4755 0.0000 C 0 0 1 0 0 0 0 0 0 0 0 0<br> 4.5133 -0.9511 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0<br> 5.3370 -0.4755 0.0000 C 0 0 1 0 0 0 0 0 0 0 0 0<br> 2.8660 -0.9511 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0<br> 4.2392 0.2219 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 3.6897 0.4755 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.3370 0.4755 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.5918 0.2219 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.5133 0.9511 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.8660 -1.9022 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0<br> 4.5133 -1.9022 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.8660 0.9511 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 3.6897 -2.3777 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 6.8418 -1.6832 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.5133 1.9022 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.8660 1.9022 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 3.6897 2.3777 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.0597 -1.6022 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.6284 -1.2740 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.0496 -1.1875 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.3760 0.8266 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 3.6795 0.4887 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.9476 0.3679 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.5490 1.0581 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 6.1840 0.4057 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.4989 0.8349 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.8660 -2.5222 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.0503 -2.2122 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 3.6897 -2.9977 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 6.3879 -2.1055 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 7.2641 -2.1371 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 7.2957 -1.2609 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.0503 2.2122 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 3.6897 2.9977 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.0000 -3.0222 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.0000 3.0222 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 1 8 1 0 0 0 0<br> 1 16 1 0 0 0 0<br> 14 2 1 6 0 0 0<br> 2 39 1 0 0 0 0<br> 3 20 1 0 0 0 0<br> 3 40 1 0 0 0 0<br> 4 7 1 0 0 0 0<br> 4 12 1 0 0 0 0<br> 4 18 1 0 0 0 0<br> 5 6 1 0 0 0 0<br> 5 8 1 0 0 0 0<br> 5 9 1 1 0 0 0<br> 5 10 1 0 0 0 0<br> 6 7 1 0 0 0 0<br> 6 15 1 0 0 0 0<br> 6 22 1 1 0 0 0<br> 7 11 1 0 0 0 0<br> 7 23 1 6 0 0 0<br> 8 14 1 0 0 0 0<br> 8 24 1 1 0 0 0<br> 9 12 1 0 0 0 0<br> 9 25 1 0 0 0 0<br> 9 26 1 0 0 0 0<br> 10 13 2 0 0 0 0<br> 10 16 1 0 0 0 0<br> 11 13 1 0 0 0 0<br> 11 27 1 0 0 0 0<br> 11 28 1 0 0 0 0<br> 12 29 1 0 0 0 0<br> 12 30 1 0 0 0 0<br> 13 19 1 0 0 0 0<br> 14 17 1 0 0 0 0<br> 14 31 1 0 0 0 0<br> 15 17 2 0 0 0 0<br> 15 32 1 0 0 0 0<br> 16 20 2 0 0 0 0<br> 17 33 1 0 0 0 0<br> 18 34 1 0 0 0 0<br> 18 35 1 0 0 0 0<br> 18 36 1 0 0 0 0<br> 19 21 2 0 0 0 0<br> 19 37 1 0 0 0 0<br> 20 21 1 0 0 0 0<br> 21 38 1 0 0 0 0<br>M END
Compound Name
Morphine
CID
5288826
Molecular Formula
C17H19NO3
Molecular Weight
285
No. Hydrogen Bond Acceptors
4
No. Hydrogen Bond Donors
2
Similar Applications
Reversed Phase
Analysis of Fat soluble Vitamins (A, E and K) Using a Kinetex 2.6u Biphenyl 50x3.0mm Column
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 3.0 mm, Ea
26505
Reversed Phase
Extraction of Pain Panel (Drugs of Abuse) in Human Serum from Phree PLR Using a Kinetex 2.6u Biphenyl 50x3.0mm
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 3.0 mm, Ea
26504
Reversed Phase
Fast Screening Method for 86 Forensic Analytes in Human Urine by LC-MS/MS
Luna 5 µm C18(2) 100 Å, LC Column 50 x 2 mm, Ea
25864
Reversed Phase
Methanol/Acetonitrile (0:100) Impact on Selectivity for Kinetex 2.6 µm C18
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 4.6 mm, Ea
25664
Reversed Phase
Methanol/Acetonitrile (20:80) Impact on Selectivity for Kinetex 2.6 µm C18
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 4.6 mm, Ea
25663
Reversed Phase
Methanol/Acetonitrile (40:60) Impact on Selectivity for Kinetex 2.6 µm C18
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 4.6 mm, Ea
25662
Reversed Phase
Methanol/Acetonitrile (60:40) Impact on Selectivity for Kinetex 2.6 µm C18
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 4.6 mm, Ea
25661
Reversed Phase
Methanol/Acetonitrile (80:20) Impact on Selectivity for Kinetex 2.6 µm C18
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 4.6 mm, Ea
25660
Reversed Phase
Methanol/Acetonitrile (100:0) Impact on Selectivity for 2.6 µm Kinetex C18
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 4.6 mm, Ea
25659
Reversed Phase
Methanol/Acetonitrile (0:100) Impact on Phenyl Selectivity for Kinetex 2.6 µm F5
Kinetex 2.6 µm F5 100 Å, LC Column 50 x 4.6 mm, Ea
25658
Reversed Phase
Methanol/Acetonitrile (20:80) Impact on Phenyl Selectivity for Kinetex 2.6 µm F5
Kinetex 2.6 µm F5 100 Å, LC Column 50 x 4.6 mm, Ea
25657
Reversed Phase
Methanol/Acetonitrile (40:60) Impact on Phenyl Selectivity for Kinetex 2.6 µm F5
Kinetex 2.6 µm F5 100 Å, LC Column 50 x 4.6 mm, Ea
25656
Reversed Phase
Methanol/Acetonitrile (60:40) Impact on Phenyl Selectivity for Kinetex 2.6 µm F5
Kinetex 2.6 µm F5 100 Å, LC Column 50 x 4.6 mm, Ea
25655
Reversed Phase
Methanol/Acetonitrile (80:20) Impact on Phenyl Selectivity for Kinetex 2.6 µm F5
Kinetex 2.6 µm F5 100 Å, LC Column 50 x 4.6 mm, Ea
25654
Reversed Phase
Methanol/Acetonitrile (100:0) Impact on Phenyl Selectivity for 2.6 µm Kinetex F5
Kinetex 2.6 µm F5 100 Å, LC Column 50 x 4.6 mm, Ea
25653
Reversed Phase
Methanol/Acetonitrile (0:100) Impact on Phenyl Selectivity for Kinetex 2.6 µm Phenyl-Hexyl
Kinetex 2.6 µm Phenyl-Hexyl 100 Å, LC Column 50 x 4.6 mm, Ea
25652
Reversed Phase
Methanol/Acetonitrile (20:80) Impact on Phenyl Selectivity for Kinetex 2.6 µm Phenyl-Hexyl
Kinetex 2.6 µm Phenyl-Hexyl 100 Å, LC Column 50 x 4.6 mm, Ea
25651
Reversed Phase
Methanol/Acetonitrile (40:60) Impact on Phenyl Selectivity for Kinetex 2.6 µm Phenyl-Hexyl
Kinetex 2.6 µm Phenyl-Hexyl 100 Å, LC Column 50 x 4.6 mm, Ea
25650
Reversed Phase
Methanol/Acetonitrile (60:40) Impact on Phenyl Selectivity for Kinetex 2.6 µm Phenyl-Hexyl
Kinetex 2.6 µm Phenyl-Hexyl 100 Å, LC Column 50 x 4.6 mm, Ea
25649
Reversed Phase
Methanol/Acetonitrile (80:20) Impact on Phenyl Selectivity for Kinetex 2.6 µm Phenyl-Hexyl
Kinetex 2.6 µm Phenyl-Hexyl 100 Å, LC Column 50 x 4.6 mm, Ea
25648
Reversed Phase
Methanol/Acetonitrile (100:0) Impact on Phenyl Selectivity for Kinetex 2.6 µm Phenyl-Hexyl
Kinetex 2.6 µm Phenyl-Hexyl 100 Å, LC Column 50 x 4.6 mm, Ea
25647
Reversed Phase
Methanol/Acetonitrile (0:100) Impact on Phenyl Selectivity for Kinetex 2.6 µm Biphenyl
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 4.6 mm, Ea
25646
Reversed Phase
Methanol/Acetonitrile (20:80) Impact on Phenyl Selectivity for Kinetex 2.6 µm Biphenyl
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 4.6 mm, Ea
25645
Reversed Phase
Methanol/Acetonitrile (40:60) Impact on Phenyl Selectivity for Kinetex 2.6 µm Biphenyl
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 4.6 mm, Ea
25644
Reversed Phase
Methanol/Acetonitrile (60:40) Impact on Phenyl Selectivity for Kinetex 2.6 µm Biphenyl
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 4.6 mm, Ea
25643
Reversed Phase
Methanol/Acetonitrile (80:20) Impact on Phenyl Selectivity for Kinetex 2.6 µm Biphenyl
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 4.6 mm, Ea
25642
Reversed Phase
Methanol/Acetonitrile (100:0) Impact on Phenyl Selectivity for Kinetex 2.6 µm Biphenyl
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 4.6 mm, Ea
25641
Reversed Phase
Extraction of Opiates in Human Serum Using Strata-X PRO and a Kinetex 2.6 µm Biphenyl LC Column
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 3.0 mm, Ea
25490
Reversed Phase
Pain Panel from Urine using Strata DE SLE and a Kinetex Biphenyl Core-Shell LC Column
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 2.1 mm, Ea
24555
Reversed Phase
Workplace drug monitoring using Luna Omega 5um Polar C18 50x2.1mm
Luna Omega 5 µm Polar C18 100Å, LC Column 50 x 2.1 mm, EA
24156
Reversed Phase
Workplace drug monitoring using Luna Omega 3um Polar C18 50x2.1mm
Luna Omega 3 µm Polar C18 100 Å, LC Column 50 x 2.1 mm, Ea
24155
Reversed Phase
Workplace drug monitoring using Luna Omega 1.6um Polar C18 50x2.1mm
Luna Omega 1.6µm Polar C18 100Å, LC Column 50 x 2.1 mm, EA
24154
Reversed Phase
SAMHSA workplace drug testing panel using Luna Omega Polar C18 50x2.1mm
Luna Omega 1.6µm Polar C18 100Å, LC Column 50 x 2.1 mm, EA
23588
Reversed Phase
7.5 min Pain Panel on Kinetex 2.6µm Biphenyl, 30x2.1mm ESI+
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 30 x 2.1 mm, Ea
23560
Reversed Phase
Drugs of Abuse by LCMS using Kinetex 1.7u Biphenyl 50x2.1mm
Kinetex 1.7 µm Biphenyl 100 Å, LC Column 50 x 2.1 mm, Ea
23445
Reversed Phase
Drugs of Abuse by LCMS using Kinetex 1.7u EVO C18 50x2.1mm
Kinetex 1.7 µm EVO C18 100 Å, LC Column 50 x 2.1 mm, Ea
23444
Reversed Phase
Drugs of Abuse by LCMS using Luna Omega 1.6u C18 50x2.1mm
Luna Omega 1.6µm C18 100Å, LC Column 50 x 2.1 mm, EA
23443
Reversed Phase
Fast Pain Panel ESI+
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 30 x 2.1 mm, Ea
23384
Improved Performance
ZB-5MSplus Drugs of Abuse
Zebron ZB-5MSplus, GC Cap. Column 30 m x 0.25 mm x 0.25 µm, EA
23258
Reversed Phase
Opiates at high pH using Kinetex 5u EVO C18 50 x 2.1 mm
Kinetex 5 µm EVO C18 100 Å, LC Column 50 x 2.1 mm, Ea
22715
Reversed Phase
Full Pain Panel using Kinetex 2.6u Biphenyl 50x2.1mm
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 2.1 mm, Ea
22122
Reversed Phase
Fast Pain Panel using Kinetex 2.6 u Biphenyl 50x3.0mm
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 3.0 mm, Ea
22121
Reversed Phase
Full Pain Panel using Kinetex 5um Biphenyl 50x3.0mm
Kinetex 5 µm Biphenyl 100 Å, LC Column 50 x 3.0 mm, Ea
22120
Reversed Phase
Pain Panel Opiates using Kinetex 2.6u Biphenyl 50x3.0mm
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 3.0 mm, Ea
22108
Reversed Phase
Full Pain Panel using Kinetex 2.6u Biphenyl 50x3.0mm
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 3.0 mm, Ea
22104
Reversed Phase
Extraction of Bases from Oral Fluid Using Quantisol (OFC Device) on Kinetex Phenyl Hexyl column
Kinetex 2.6 µm Phenyl-Hexyl 100 Å, LC Column 50 x 4.6 mm, Ea
22093
Reversed Phase
Extraction of Bases from Oral Fluid Using Orasure (OFC Device) on Kinetex Phenyl Hexyl column
Kinetex 2.6 µm Phenyl-Hexyl 100 Å, LC Column 50 x 4.6 mm, Ea
22092
Reversed Phase
Morphine isobars using Kinetex 2.6u Biphenyl 50x2.1mm
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 2.1 mm, Ea
21992
Reversed Phase
Opiates using Kinetex 2.6u Biphenyl 50x2.1mm
Kinetex 2.6 µm Biphenyl 100 Å, LC Column 50 x 2.1 mm, Ea
21972
Reversed Phase
Pain Panel using Kinetex Phenyl Hexyl 2.6u 50x4.6mm
Kinetex 2.6 µm Phenyl-Hexyl 100 Å, LC Column 50 x 4.6 mm, Ea
20852
Reversed Phase
Pain Panel using Strata-X-Drug B and Kinetex Phenyl-Hexyl 2.6u 50x4.6mm
Kinetex 2.6 µm Phenyl-Hexyl 100 Å, LC Column 50 x 4.6 mm, Ea
20847
Application Specific
Cocaine and opiates by GCMS on a ZB-Drug-1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
20811
Standard
Cocaine and opiates by GCMS on a ZB-5MS
Zebron ZB-5MS, GC Cap. Column 20 m x 0.18 mm x 0.18 µm, Ea
20809
Reversed Phase
Pain Panel Opiates by LC/MS using Kinetex 2.6u C18 50x2.1mm
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 2.1 mm, Ea
20692
Reversed Phase
Pain Panel/Drug Screening by LCMS using Kinetex 2.6u C18 50x3.0mm
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 3 mm, Ea
20689
Reversed Phase
Pain Panel Mix-41 in Human Urine on Luna 3u, PFP(2), 50x3 by LC-MS/MS
Luna 3 µm PFP(2) 100 Å, LC Column 50 x 3 mm, Ea
20594
Reversed Phase
Pain Panel Mix-41 in Human Urine on Kinetex 2.6u, PFP, 50x3 by LC-MS/MS
Kinetex 2.6 µm PFP 100 Å, LC Column 50 x 3 mm, Ea
20593
Reversed Phase
Pain Panel Mix-41 in Human Urine on Kinetex 2.6u, Phenyl-Hexyl, 50x2.1 by LC-MS/MS
Kinetex 2.6 µm Phenyl-Hexyl 100 Å, LC Column 50 x 2.1 mm, Ea
20592
Reversed Phase
Pain Panel Mix-41 in Human Urine on Kinetex 2.6u, XB-C18, 50x3 by LC-MS/MS
Kinetex 2.6 µm XB-C18 100 Å, LC Column 50 x 3 mm, Ea
20591
Reversed Phase
Pain Panel Mix-41 in Human Urine on Kinetex 2.6u, C18, 50x3 by LC-MS/MS
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 3 mm, Ea
20590
Reversed Phase
LC/MS/MS of Extended Opiates from urine using Strata-X-Drug B on a Kinetex C18 2.6µm, 50x2.1mm
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 2.1 mm, Ea
19705
Application Specific
Opiates from urine using Strata-X-Drug B and Zebron Drug-1 10x0.18x0.18
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
19600
Reversed Phase
Kinetex SAMHSA LC/MS Run
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 2.1 mm, Ea
19593
Reversed Phase
Narcotics 8-mix at Neutral pH on Kinetex 2.6 µm C18, 50 x 2.1mm
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 2.1 mm, Ea
19184
Reversed Phase
Pain Panel on Kinetex C18 2.6µm 50 x 2.1 mm by LC/MS
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 2.1 mm, Ea
19177
Reversed Phase
Pain Panel with and without sample focusing on Kinetex C18 2.6µm 50 x 2.1 mm by LC/MS
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 2.1 mm, Ea
19167
Hydrophilic Interaction
Morphine and Metabolites on Kinetex 2.6µm HILIC batch #48 50x4.6mm
Kinetex 2.6 µm HILIC 100 Å, LC Column 50 x 4.6 mm, Ea
18882
Reversed Phase
NIDA-5 Extracted from Human Urine at Cutoff - Kinetex 2.6µm C18 50 x 2.1mm ID by LCMSMS
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 2.1 mm, Ea
18851
Reversed Phase
Pain panel extracted from human urine at cutoff - Kinetex C18 2.6µm 50x2.1mm LCMSMS
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 2.1 mm, Ea
18850
Reversed Phase
Extraction of Opiates-NIDA5 Using Strata X-C on Kinetex 2.6µm C18 50 x 2.1mm ID by LCMS
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 2.1 mm, Ea
18846
Application Specific
Healthcare opiates (propyl derivatives) from urine by Strata-XC on a ZB-Drug1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
18771
Reversed Phase
Extraction of Healthcare Opiates using strata X-C on Kinetex 2.6µm C18 50 x 2.1mm ID by LC/MS
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 2.1 mm, Ea
18716
Reversed Phase
Healthcare Opiates on Kinetex 2.6µm C18 50 x 2.1 mm ID by LC/MS
Kinetex 2.6 µm C18 100 Å, LC Column 50 x 2.1 mm, Ea
18715
Reversed Phase
Extraction of Healthcare Opiates using strata X-C on Kinetex 2.6µm PFP 50 x 2.1mm ID by LCMS
Kinetex 2.6 µm PFP 100 Å, LC Column 50 x 2.1 mm, Ea
18670
Reversed Phase
Healthcare Opiates on Kinetex 2.6µm PFP 50 x 2.1mm ID by LC/MS
Kinetex 2.6 µm PFP 100 Å, LC Column 50 x 2.1 mm, Ea
18616
Application Specific
Expanded healthcare opiates (propyl derivatives) from urine by Strata-XC on a ZB-Drug1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
18513
Application Specific
Opiates from urine by Strata-XC on a ZB-Drug1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
18301
Application Specific
Expanded healthcare opiates (propyl derivatives) from urine by Screen C on a ZB-Drug1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
18200
Application Specific
Healthcare opiates (propyl derivatives) by MSD on a ZB-Drug1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
18181
Application Specific
Drug screen by MSD on a ZB-Drug1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
18175
Application Specific
Opiates from urine by Screen C on a ZB-Drug1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
18035
Application Specific
6-MAM and Interferences by MSD on a ZB-Drug1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
17931
6-MAM and Interferences by MSD on a ZB-5MSi
17930
Healthcare Opiates from Urine by Screen C on a ZB-5MSi
17908
Application Specific
Healthcare Opiates from Urine by Screen C on a ZB-Drug-1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
17907
Application Specific
Healthcare Opiates by MSD on a ZB-Drug1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
17899
Opiates by MSD on a ZB-5MSi
17895
Application Specific
Opiates by MSD on a ZB-Drug1
Zebron ZB-Drug-1, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
17806
Opiates by MSD on a ZB-1MS
17616
Opiates by MSD on a ZB-XLB
17612
Standard
Opiates by MSD on a ZB-5MS
Zebron ZB-5MS, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
16741
Standard
Opiates by MSD on a ZB-5MS
Zebron ZB-5MS, GC Cap. Column 10 m x 0.18 mm x 0.18 µm, Ea
16733
Opiates expanded run by MSD on a ZB-5MSi
16555
Standard
Opiates expanded run by MSD on a ZB-XLB
Zebron ZB-XLB, GC Cap. Column 30 m x 0.25 mm x 0.25 µm, Ea
16554
Standard
Drug Screen on ZB-XLB
Zebron ZB-XLB, GC Cap. Column 30 m x 0.25 mm x 0.50 µm, Ea
16463
Drug screen on ZB-5MSi
16421
Standard
Common Drug Screen on ZB-50
Zebron ZB-50, GC Cap. Column 30 m x 0.25 mm x 0.25 µm, Ea
16012
Standard
Common Drug Screen on ZB-35
Zebron ZB-35, GC Cap. Column 30 m x 0.25 mm x 0.25 µm, Ea
16010
Standard
Common Drug Screen on ZB-5MS
Zebron ZB-5MS, GC Cap. Column 20 m x 0.18 mm x 0.18 µm, Ea
16009
Common Drug Screen on ZB-1MS
16008